Cancer research investment awards and funding by type of science
| Type of science | All funders where investment data were available | Cancer Research UK | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of awards | Percentage of total | Sum investment (£) | Percentage of total | Mean award, £ (SD) | Median award, £ (IQR) | Number of awards | Percentage of all oncology research awards | |
| Preclinical | 2845 | 66.2% | £1 485 997 379 | 62.2% | 522 318 (1 006 600) | 240 974 (132 188–490 872) | 1809 | 55.1% |
| Phase I-III | 303 | 7.0% | £223 060 276 | 9.3% | 736 172 (3 361 312) | 178 535 (70 934–502 399) | 647 | 19.7% |
| Product development | 172 | 4.0% | £104 214 364 | 4.4% | 605 897 (2 213 394) | 193 051 (75 270–360 813) | 52 | 1.6% |
| Cross-disciplinary | 441 | 10.3% | £315 145 351 | 13.2% | 714 615 (1 586 882) | 238 523 (126 589–703 764) | 328 | 10.0% |
| Public health | 512 | 11.9% | £254 333 282 | 10.6% | 496 744 (1 000 757) | 209 364 (82 870–383 623) | 443 | 13.5% |
| Unable to specify | 26 | 0.6% | £5 401 666 | 0.2% | n/a | n/a | 5 | 0.2% |
| Total | 4299 | £2 388 152 318 | 555 513 (1 429 510) | 231 559 (114 619–487 063) | 3284 | |||
All investment reported in 2013 UK pounds.